We are analyzing https://link.springer.com/article/10.1007/bf00205646.

Title:
Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas | Cancer Immunology, Immunotherapy
Description:
T lymphocytes were isolated from tumor biopsies in 13 patients with breast carcinomas. Immunohistology with monoclonal antibodies confirmed the presence of mononuclear cell infiltrates composed primarily of T lymphocytes in all tumors studied. While the proportion of T lymphocytes expressing the T4 or the T8 surface marker varied from tumor to tumor as determined by morphometric analysis, T8+ cells were more numerous than T4+ cells in 8/12 breast tumors studied. Relatively few T cells (<10% in 11/12 tumors) were in an activated state as judged by the surface expression of HLA-DR antigens or the receptor for interleukin-2 (IL-2). In 1 case 20% of the infiltrating mononuclear cells were expressing the IL-2 receptor. The tumor infiltrating lymphocytes (TIL) recovered from 10 tumors were cloned in a microculture system that permits proliferation of nearly 100% of normal peripheral blood T lymphocytes (PBL-T). In contrast to normal and autologous PBL-T, frequencies of proliferating T lymphocyte precursors (PTL-P) were depressed (<0.01) in 7/10 TIL preparations indicating a decreased responsiveness of TIL to phytohemagglutinin at the single-cell level. The frequency of PTL-P was noticeably higher in 2 cases (0.03 and 0.09) and close to normal in 1 case (0.39). A total of 170 clones were expanded in vitro and analyzed for different functional capabilities. Most of these clones expressed the T4+/T8-phenotype (73%) and strikingly 53% of these T4+/T8− clones were cytolytic in a lectin-dependent assay, a functional subset which is uncommon among normal PBL-T. Some clones (10%) lysed allogeneic breast tumor cells (MCF7). Only 15% of the clones displayed natural killer activity. Among the cytolytic clones, 17 of 31 tested were also IL-2 producers irrespective of the T4 or T8 phenotype. Our results show that human mammary carcinomas contain many infiltrating T cells with cytolytic potential. Interestingly, among the proliferating cytolytic T cell clones (56% of the microcultures), many expressed the T4+/T8− phenotype. These findings may indicate that the in situ cytolytic reaction (against unknown antigens) is associated preferentially with class II antigens.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,016 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

google, scholar, cancer, human, cells, lymphocytes, breast, analysis, cell, infiltrating, moretta, tumor, article, tumors, clonal, cytolytic, immunol, blood, clones, activity, cytotoxic, int, characterization, antigens, functional, patients, lymphocyte, access, exp, med, carcinoma, privacy, cookies, content, research, carcinomas, whiteside, miescher, hurlimann, surface, peripheral, autologous, melanoma, vose, data, information, publish, search, situ, fliedner,

Topics {✒️}

interleukin-2-dependent t-cell cultures month download article/chapter human breast carcinoma human tumour-lymphocyte interaction human tumor-infiltrating lymphocytes inflammatory cellular infiltrate t-cell-mediated cytotoxicity cytotoxic t-lymphocyte response cells t-cell lymphoma t-cell clones capable tumour-reactive lymphocytes stimulated breast cancer infiltrates nk-cell activity human mammary carcinomas human breast cancer tumor infiltrating lymphocytes tumor-infiltrating lymphocytes infiltrating mononuclear cells breast cancer microenvironment privacy choices/manage cookies invasive breast cancer human ovarian tumors express cytolytic activity lymphocyte precursors breast carcinomas cell-mediated immunity human malignant tumors malignant breast disease full article pdf lectin-dependent assay depressed immune competence cancer research campaign single-cell level cell growth factor human leukocyte antigens von fliedner cloned human cytotoxic article cancer immunology breast cancer patients host cell populations cell surface antigens hla-dr antigens defined clinical stages cells cd4-positive lymph-node lymphocytes european economic area check access endogenous enzyme hexosaminidase del prete gf rossi-ferrini pl

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas
         description:T lymphocytes were isolated from tumor biopsies in 13 patients with breast carcinomas. Immunohistology with monoclonal antibodies confirmed the presence of mononuclear cell infiltrates composed primarily of T lymphocytes in all tumors studied. While the proportion of T lymphocytes expressing the T4 or the T8 surface marker varied from tumor to tumor as determined by morphometric analysis, T8+ cells were more numerous than T4+ cells in 8/12 breast tumors studied. Relatively few T cells (<10% in 11/12 tumors) were in an activated state as judged by the surface expression of HLA-DR antigens or the receptor for interleukin-2 (IL-2). In 1 case 20% of the infiltrating mononuclear cells were expressing the IL-2 receptor. The tumor infiltrating lymphocytes (TIL) recovered from 10 tumors were cloned in a microculture system that permits proliferation of nearly 100% of normal peripheral blood T lymphocytes (PBL-T). In contrast to normal and autologous PBL-T, frequencies of proliferating T lymphocyte precursors (PTL-P) were depressed (<0.01) in 7/10 TIL preparations indicating a decreased responsiveness of TIL to phytohemagglutinin at the single-cell level. The frequency of PTL-P was noticeably higher in 2 cases (0.03 and 0.09) and close to normal in 1 case (0.39). A total of 170 clones were expanded in vitro and analyzed for different functional capabilities. Most of these clones expressed the T4+/T8-phenotype (73%) and strikingly 53% of these T4+/T8− clones were cytolytic in a lectin-dependent assay, a functional subset which is uncommon among normal PBL-T. Some clones (10%) lysed allogeneic breast tumor cells (MCF7). Only 15% of the clones displayed natural killer activity. Among the cytolytic clones, 17 of 31 tested were also IL-2 producers irrespective of the T4 or T8 phenotype. Our results show that human mammary carcinomas contain many infiltrating T cells with cytolytic potential. Interestingly, among the proliferating cytolytic T cell clones (56% of the microcultures), many expressed the T4+/T8− phenotype. These findings may indicate that the in situ cytolytic reaction (against unknown antigens) is associated preferentially with class II antigens.
         datePublished:
         dateModified:
         pageStart:169
         pageEnd:178
         sameAs:https://doi.org/10.1007/BF00205646
         keywords:
            Breast Carcinoma
            Tumor Infiltrate Lymphocyte
            Human Breast Carcinoma
            Killer Activity
            Breast Tumor Cell
            Oncology
            Immunology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:23
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Theresa L. Whiteside
               affiliation:
                     name:Ludwig Institute for Cancer Research
                     address:
                        name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sylvia Miescher
               affiliation:
                     name:Ludwig Institute for Cancer Research
                     address:
                        name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jean Hurlimann
               affiliation:
                     name:University of Lausanne Switzerland
                     address:
                        name:Department of Pathology, University of Lausanne Switzerland, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lorenzo Moretta
               affiliation:
                     name:Ludwig Institute for Cancer Research
                     address:
                        name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Vladimir von Fliedner
               affiliation:
                     name:Ludwig Institute for Cancer Research
                     address:
                        name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas
      description:T lymphocytes were isolated from tumor biopsies in 13 patients with breast carcinomas. Immunohistology with monoclonal antibodies confirmed the presence of mononuclear cell infiltrates composed primarily of T lymphocytes in all tumors studied. While the proportion of T lymphocytes expressing the T4 or the T8 surface marker varied from tumor to tumor as determined by morphometric analysis, T8+ cells were more numerous than T4+ cells in 8/12 breast tumors studied. Relatively few T cells (<10% in 11/12 tumors) were in an activated state as judged by the surface expression of HLA-DR antigens or the receptor for interleukin-2 (IL-2). In 1 case 20% of the infiltrating mononuclear cells were expressing the IL-2 receptor. The tumor infiltrating lymphocytes (TIL) recovered from 10 tumors were cloned in a microculture system that permits proliferation of nearly 100% of normal peripheral blood T lymphocytes (PBL-T). In contrast to normal and autologous PBL-T, frequencies of proliferating T lymphocyte precursors (PTL-P) were depressed (<0.01) in 7/10 TIL preparations indicating a decreased responsiveness of TIL to phytohemagglutinin at the single-cell level. The frequency of PTL-P was noticeably higher in 2 cases (0.03 and 0.09) and close to normal in 1 case (0.39). A total of 170 clones were expanded in vitro and analyzed for different functional capabilities. Most of these clones expressed the T4+/T8-phenotype (73%) and strikingly 53% of these T4+/T8− clones were cytolytic in a lectin-dependent assay, a functional subset which is uncommon among normal PBL-T. Some clones (10%) lysed allogeneic breast tumor cells (MCF7). Only 15% of the clones displayed natural killer activity. Among the cytolytic clones, 17 of 31 tested were also IL-2 producers irrespective of the T4 or T8 phenotype. Our results show that human mammary carcinomas contain many infiltrating T cells with cytolytic potential. Interestingly, among the proliferating cytolytic T cell clones (56% of the microcultures), many expressed the T4+/T8− phenotype. These findings may indicate that the in situ cytolytic reaction (against unknown antigens) is associated preferentially with class II antigens.
      datePublished:
      dateModified:
      pageStart:169
      pageEnd:178
      sameAs:https://doi.org/10.1007/BF00205646
      keywords:
         Breast Carcinoma
         Tumor Infiltrate Lymphocyte
         Human Breast Carcinoma
         Killer Activity
         Breast Tumor Cell
         Oncology
         Immunology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:23
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Theresa L. Whiteside
            affiliation:
                  name:Ludwig Institute for Cancer Research
                  address:
                     name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sylvia Miescher
            affiliation:
                  name:Ludwig Institute for Cancer Research
                  address:
                     name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jean Hurlimann
            affiliation:
                  name:University of Lausanne Switzerland
                  address:
                     name:Department of Pathology, University of Lausanne Switzerland, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lorenzo Moretta
            affiliation:
                  name:Ludwig Institute for Cancer Research
                  address:
                     name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Vladimir von Fliedner
            affiliation:
                  name:Ludwig Institute for Cancer Research
                  address:
                     name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:23
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Ludwig Institute for Cancer Research
      address:
         name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
         type:PostalAddress
      name:Ludwig Institute for Cancer Research
      address:
         name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
         type:PostalAddress
      name:University of Lausanne Switzerland
      address:
         name:Department of Pathology, University of Lausanne Switzerland, Switzerland
         type:PostalAddress
      name:Ludwig Institute for Cancer Research
      address:
         name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
         type:PostalAddress
      name:Ludwig Institute for Cancer Research
      address:
         name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Theresa L. Whiteside
      affiliation:
            name:Ludwig Institute for Cancer Research
            address:
               name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
               type:PostalAddress
            type:Organization
      name:Sylvia Miescher
      affiliation:
            name:Ludwig Institute for Cancer Research
            address:
               name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
               type:PostalAddress
            type:Organization
      name:Jean Hurlimann
      affiliation:
            name:University of Lausanne Switzerland
            address:
               name:Department of Pathology, University of Lausanne Switzerland, Switzerland
               type:PostalAddress
            type:Organization
      name:Lorenzo Moretta
      affiliation:
            name:Ludwig Institute for Cancer Research
            address:
               name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
               type:PostalAddress
            type:Organization
      name:Vladimir von Fliedner
      affiliation:
            name:Ludwig Institute for Cancer Research
            address:
               name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
      name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
      name:Department of Pathology, University of Lausanne Switzerland, Switzerland
      name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
      name:Lausanne Branch, Ludwig Institute for Cancer Research, Epalinges, Switzerland
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(75)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.51s.

LINK . SPRINGER . COM {}